| 6.27 -0.31 (-4.71%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.79 |
1-year : | 9.71 |
| Resists | First : | 7.52 |
Second : | 8.31 |
| Pivot price | 6.89 |
|||
| Supports | First : | 6.25 |
Second : | 5.2 |
| MAs | MA(5) : | 6.55 |
MA(20) : | 7.11 |
| MA(100) : | 8.35 |
MA(250) : | 7.69 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 5.4 |
D(3) : | 7.4 |
| RSI | RSI(14): 29.4 |
|||
| 52-week | High : | 11 | Low : | 5.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RNAC ] has closed above bottom band by 3.7%. Bollinger Bands are 48% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.64 - 6.68 | 6.68 - 6.71 |
| Low: | 6.14 - 6.19 | 6.19 - 6.23 |
| Close: | 6.2 - 6.27 | 6.27 - 6.33 |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Mon, 12 Oct 2026
Cartesian Therapeutics, Inc. (RNAC) options chain - Yahoo Finance Australia
Fri, 02 Oct 2026
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Fri, 02 Oct 2026
Four new hires received the right to buy 121,900 shares at Cartesian Therapeutics - Stock Titan
Mon, 10 Aug 2026
Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target - RTTNews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 1.149e+007 (%) |
| Held by Institutions | 52.1 (%) |
| Shares Short | 1,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.605e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -8 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 679.6 % |
| Return on Equity (ttm) | -17.5 % |
| Qtrly Rev. Growth | 1.48e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -9.29306e+007 |
| Qtrly Earnings Growth | -5.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -77 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.79 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 1.86e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|